NEW YORK (GenomeWeb News) – Researchers at the Dana-Farber/Harvard Cancer Center will use HistoRx’s Aqua biomarker profiling technology in cancer studies and cancer treatment research, the company said Thursday.
More than 900 researchers at DF/HCC will use the company’s PM-2000 tissue analysis tool, which was purchased by Brigham and Women’s Hospital for its pathology core facility in 2005.
The core facility is a service center that provides tissue-based tests and analysis for several institutions, including Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Children’s Hospital Boston, Beth Israel Deaconess Hospital, and Massachusetts General Hospital.
The company’s Aqua technology is used to measure biomarker concentration with subcellular resolution in order to understand the safety and effectiveness of new drugs and companion diagnostics.
The PM-2000 system is used to measure protein biomarkers in tissue and in tissue microarrays that are based on fluorescent immunohistochemical methods.